Obstetric outcomes of participants in different groups undergoing cesarean section
| Group A n=17 | Group B n=19 | Group C n=14 | A vs B | A vs C | B vs C | |
| Thromboembolism | ||||||
| 6 weeks post partum | 2 (11.8) | 1 (5.3) | 0 (0.0) | 0.075 | <0.001 | 0.015 |
| 3 months post partum | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Thrombophlebitis | 6 (35.3) | 3 (15.8) | 2 (14.3) | 0.064 | 0.032 | 0.378 |
| Postpartum hemorrhage | 4 (23.5) | 1 (5.3) | 0 (0.0) | 0.017 | 0.002 | 0.015 |
| Within 24 hours | 3 (17.6) | 1 (5.3) | 0 (0.0) | 0.019 | 0.003 | 0.015 |
| Within 6 weeks | 1 (5.9) | 0 (0.0) | 0 (0.0) | 0.124 | 0.096 | – |
| SEH | 1 (5.9) | 0 (0.0) | 0 (0.0) | 0.124 | 0.096 | – |
| Dalteparin side effects | ||||||
| Bleeding | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Thrombocytopenia | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Thrombotic episodes | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Skin allergy | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
Data are expressed as n (%).
Data in bold indicates significant difference.
Group A: fixed dose group; group B: weight group; group C: anti-FXa+weight group.
FXa, factor Xa; SEH, obstetric spinal epidural hematoma.